X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs VENUS REMEDIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA VENUS REMEDIES TORRENT PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 44.1 -8.3 - View Chart
P/BV x 6.2 0.1 4,809.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
VENUS REMEDIES
Mar-17
TORRENT PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,550143 1,085.4%   
Low Rs1,14465 1,759.2%   
Sales per share (Unadj.) Rs354.7324.2 109.4%  
Earnings per share (Unadj.) Rs40.16.4 625.2%  
Cash flow per share (Unadj.) Rs64.240.6 158.3%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1366.0 74.6%  
Shares outstanding (eoy) m169.2212.34 1,371.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.3 1,184.7%   
Avg P/E ratio x33.616.2 207.3%  
P/CF ratio (eoy) x21.02.6 819.0%  
Price / Book Value ratio x4.90.3 1,736.7%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,282 17,774.9%   
No. of employees `00014.70.9 1,627.9%   
Total wages/salary Rs m11,353251 4,522.9%   
Avg. sales/employee Rs Th4,083.04,430.1 92.2%   
Avg. wages/employee Rs Th772.3278.0 277.8%   
Avg. net profit/employee Rs Th461.387.6 526.6%   
INCOME DATA
Net Sales Rs m60,0214,000 1,500.4%  
Other income Rs m2,98823 13,164.8%   
Total revenues Rs m63,0094,023 1,566.2%   
Gross profit Rs m13,493785 1,719.4%  
Depreciation Rs m4,086422 969.2%   
Interest Rs m3,085344 897.5%   
Profit before tax Rs m9,31042 22,114.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529-37 -6,834.3%   
Profit after tax Rs m6,78179 8,573.2%  
Gross profit margin %22.519.6 114.6%  
Effective tax rate %27.2-87.9 -30.9%   
Net profit margin %11.32.0 571.4%  
BALANCE SHEET DATA
Current assets Rs m52,6232,606 2,019.1%   
Current liabilities Rs m52,0221,980 2,627.0%   
Net working cap to sales %1.015.6 6.4%  
Current ratio x1.01.3 76.9%  
Inventory Days Days120128 93.2%  
Debtors Days Days7643 176.7%  
Net fixed assets Rs m85,0165,353 1,588.1%   
Share capital Rs m846123 685.7%   
"Free" reserves Rs m45,3764,393 1,033.0%   
Net worth Rs m46,2224,516 1,023.5%   
Long term debt Rs m41,1151,618 2,540.8%   
Total assets Rs m142,4328,291 1,717.9%  
Interest coverage x4.01.1 358.0%   
Debt to equity ratio x0.90.4 248.2%  
Sales to assets ratio x0.40.5 87.3%   
Return on assets %6.95.1 135.8%  
Return on equity %14.71.8 837.6%  
Return on capital %14.26.3 225.7%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m14,5800-   
Fx outflow Rs m3,600736 488.9%   
Net fx Rs m10,980-736 -1,491.3%   
CASH FLOW
From Operations Rs m8,942997 896.7%  
From Investments Rs m-47,070-461 10,203.7%  
From Financial Activity Rs m34,174-571 -5,984.9%  
Net Cashflow Rs m-3,655-35 10,413.1%  

Share Holding

Indian Promoters % 71.5 32.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,900.0%  
FIIs % 12.6 0.6 2,172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 66.4 13.3%  
Shareholders   26,511 20,121 131.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FULFORD INDIA  SUVEN LIFE  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 16, 2018 03:07 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - AJANTA PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS